Oppenheimer analyst Matthew Biegler raised the firm’s price target on Nurix Therapeutics to $35 from $30 and keeps an Outperform rating on the shares. The firm believes the biannual data cut from NX-5948’s ongoing Phase 1b will continue to be important for the shares and is increasingly bullish ahead of ASH. However, a fair number of investors believe the drug’s opportunity in blood cancers is baked into the current valuation, and those investors want more details on Nurix’s I&I strategy, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Nurix Therapeutics Braces for Stricter Disclosure Rules as Market Value Grows
- Nurix Therapeutics reports Q3 EPS (67c), consensus (69c)
- Nurix Therapeutics initiated with a Buy at Jefferies
- Nurix Therapeutics, Inc. (NRIX) Q3 Earnings Cheat Sheet